CRO Avania Acquires MAXIS
Avania, a global medical technology contract research organization (CRO), has acquired MAXIS, a medical technology development service provider with expertise in pre-clinical engineering, design validation and verification, regulatory affairs, field clinical services, and trial management.
MAXIS has offices in San Jose, California, and Frankfurt am Main, Germany, with additional operational staff across the regions. Avania’s has offices in the U.S., EU, and Australia.
The acquisition brings an expanded roster of subject matter experts in the global pre-clinical, clinical (in vitro diagnostics, artificial intelligence/machine learning, and Software as Medical Device), and regulatory consulting space to Avania.
“This acquisition strengthens our position as the leading MedTech focused CRO, advancing innovative medical technologies from ideation to commercialization, providing a range of highly customizable services in combination with robust global regulatory, clinical, and operational strategies to meet the unique needs of emerging OEMs,” said Sapna Hornyak, president and CEO of Avania. “The addition of MAXIS furthers our strategy and will provide us with enhanced capabilities across a broader customer base as we continue to innovate and grow.”
“MAXIS’ long-standing commitment to emerging technology companies will be greatly enhanced with Avania’s sophisticated infrastructure and extensive resources,” said Kathleen Marshall, president of MAXIS Medical. “Avania’s understanding of our strategic value in the continuum of medical technology development was compelling and decisive, and we are delighted to be able to continue our mission with the Avania team.”
Related Articles
-
Beginning October 1, 2023, the FDA’s Total Product Life Cycle Advisory Program (TAP) Pilot will expand to include the Office of Neurological and Physical Medicine Devices (OHT5).
-
On May 16-17, device developers, regulatory affairs and regulatory intelligence professionals will come together in Washington, DC, for two days of education, discussion and networking to share strategies and best practices on navigating current and on the horizon regulatory requirements.
-
The acquisition expands Veranex’s European footprint as well as the scale and scope of its clinical studies capabilities.
-
Bringing design and quality assurance processes together earlier in the device development process can reduce costs and nonconformances, while improving outcomes.
